GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a non-invasive device and digital health platform for measuring glucose levels in people with Type 2 diabetes and ...

A team of medical researchers and engineers at RSP Systems, in Denmark, working with a pair of colleagues from the Institute for Diabetes Technology, and another colleague with the University of ...

Glucotrack (GCTK) will participate in the FORGETDIABETES bionic pancreas initiative that will develop a long-term, automated insulin delivery ...

Glucotrack (Nasdaq:GCTK) announced today that it intends to participate in a bionic pancreas initiative in Europe.

Glucotrack’s Continuous Blood Glucose Monitor (CBGM) will provide real-time glucose readings to drive insulin delivery decisions for the bionic pancreas system. “We are committed to the goal ...

Glucotrack's Continuous Blood Glucose Monitor is still in the investigational stage, indicating that it is not yet commercially available, which could delay potential revenue generation.

Glucotrack will leverage next-generation artificial intelligence and machine learning-based analytics to evaluate clinical study data from its Continuous Blood Glucose Monitor (CBGM), enhancing ...

Apple's attempts to develop a non-invasive glucose monitoring feature for Apple Watch remains "many years away" from debuting ...

(Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that ...